Additional testing and follow-up may provide answers.
Encephalitis, not otherwise specified (ENOS), represents a nondiagnostic brain biopsy in cases of rapid clinical deterioration when the cause is unknown. To examine what further testing and follow-up can reveal in such cases, researchers reviewed outcomes in 58 cases of ENOS (median age, 40 [interquartile range, 23–52]; 22% with HIV).
The investigators' additional review and immunohistochemical analyses of the pathologic material from 29 patients led to a more specific diagnosis in 34%, including demyelinating disease, progressive multifocal leukoencephalopathy, glioma, lymphomatoid granulomatosis, ischemia, mesial temporal sclerosis, and lymphoma. For those who had additional follow-up and testing, diagnoses included tuberculosis, herpes si…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)